发明名称 |
Crystalline forms of 3-[5-chloro-4-[(2,4-difluorobenzyl) oxy]-6-oxopyrimidin-1(6H)-yl]-N-(2-hydroxyethyl)-4-methylbenzamide |
摘要 |
Crystalline forms of the p38 kinase inhibitor 3-[5-chloro-4-[(2,4-difluorobenzyl)oxy]-6-oxopyrimidin-1(6H)-yl]-N-(2-hydroxyethyl)-4-methylbenzamide is provided. Also provided are combinations and pharmaceutical compositions comprising the crystalline forms, and methods for the prophylaxis and/or treatment of a p38 kinase-mediated condition comprising administering to a subject a therapeutically effective amount of the crystalline forms. |
申请公布号 |
US8933088(B2) |
申请公布日期 |
2015.01.13 |
申请号 |
US201213669564 |
申请日期 |
2012.11.06 |
申请人 |
Pfizer Inc. |
发明人 |
Selbo Jon G. |
分类号 |
A01N43/54;A61K31/505;C07D239/02 |
主分类号 |
A01N43/54 |
代理机构 |
|
代理人 |
Munchhof Martha G. |
主权项 |
1. A crystalline form of 3-[5-chloro-4-[(2,4-difluorobenzyl)oxy]-6-oxopyrimidin-1(6H)-yl]-N-(2-hydroxyethyl)-4-methylbenzamide having an X-ray powder diffraction pattern comprising a peak selected from the group consisting of 11.8±0.2, 13.7±0.2, 15.8±0.2, 21.4±0.2, 21.9±0.2, 26.2±0.2, and 26.9±0.2 degrees 2 theta. |
地址 |
New York NY US |